Cargando…

重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织MMP及抗瘤效应观察

BACKGROUND AND OBJECTIVE: The aim of this study is to observe the changes of MMP-2 and its regulators, and to investigate the mechanism of the two administration sequences of recombinant human endostatin (rh-endostatin) and docetaxel. METHODS: The experiment was performed as 2 stages. Firstly, nude...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015153/
https://www.ncbi.nlm.nih.gov/pubmed/20681443
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.06.003
_version_ 1783334343242940416
collection PubMed
description BACKGROUND AND OBJECTIVE: The aim of this study is to observe the changes of MMP-2 and its regulators, and to investigate the mechanism of the two administration sequences of recombinant human endostatin (rh-endostatin) and docetaxel. METHODS: The experiment was performed as 2 stages. Firstly, nude mice with xenograft tumor were randomized into 2 groups as rh-endostatin-treated group with rh-endostatin 400 μg·d(-1), d1-d14 and docetaxel-traeted group with docetaxel 10 mg·kg(-1)·3d(-1), d1-d14. Secondly, nude mice with xenograft tumor were randomized into 3 groups as concurrent administration group (rh-endostatin 400 μg·d(-1), d1-d35, docetaxel 10 mg·kg(-1)·3d(-1), d1-d19), endo-first group (rh-endostatin 400 μg·d(-1), d1-d35, docetaxel 10 mg·kg(-1)·3d(-1), d16-d34) and model group (positive control, mice burdened tumor without treatment). The volume of tumor was measured during treatment. Detection of the expressions of MMP-2, TIMP-2, EMMPRIN and the count of microvessel density (MVD) by immunohistochemistry stain examination were carried out at the end of experiment. RESULTS: Compared with the docetaxel-treated group, more obvious down-regulation of expression of MMP-2, EMMPRIN (P=0.024, P=0.081) were observed in rh-endostatin-treated group. No significant difference was found in TIMP-2 expression between the 2 groups. In combined treatment groups, at the endpoint tumor volumes of concurrent administration group and the endo-first group were remarkably smaller than that in model group (P < 0.001, P=0.003). According to the administration procedure, concurrent administration inhibited tumor growth ber than endo-first treatment did. Both of the combined groups down-regulated the expression of MMP-2 and decreased microvessel density (P < 0.05). Compared with model group, the expression of TIMP-2 was upregulated (P=0.001) as well as EMMPRIN down-regulated (P=0.018) in concurrent administration group. Oppositely, the same results were not observed in the endo-first group. CONCLUSION: The schedule of the concurrent administration group could inhibit the tumor growth better, and it down-regulated MMP-2 expression through TIMP-2 and EMMPRIN, and thus slow down the tumor growth superiorly to another schedule of treatment.
format Online
Article
Text
id pubmed-6015153
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60151532018-07-06 重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织MMP及抗瘤效应观察 Zhongguo Fei Ai Za Zhi 基础研究 BACKGROUND AND OBJECTIVE: The aim of this study is to observe the changes of MMP-2 and its regulators, and to investigate the mechanism of the two administration sequences of recombinant human endostatin (rh-endostatin) and docetaxel. METHODS: The experiment was performed as 2 stages. Firstly, nude mice with xenograft tumor were randomized into 2 groups as rh-endostatin-treated group with rh-endostatin 400 μg·d(-1), d1-d14 and docetaxel-traeted group with docetaxel 10 mg·kg(-1)·3d(-1), d1-d14. Secondly, nude mice with xenograft tumor were randomized into 3 groups as concurrent administration group (rh-endostatin 400 μg·d(-1), d1-d35, docetaxel 10 mg·kg(-1)·3d(-1), d1-d19), endo-first group (rh-endostatin 400 μg·d(-1), d1-d35, docetaxel 10 mg·kg(-1)·3d(-1), d16-d34) and model group (positive control, mice burdened tumor without treatment). The volume of tumor was measured during treatment. Detection of the expressions of MMP-2, TIMP-2, EMMPRIN and the count of microvessel density (MVD) by immunohistochemistry stain examination were carried out at the end of experiment. RESULTS: Compared with the docetaxel-treated group, more obvious down-regulation of expression of MMP-2, EMMPRIN (P=0.024, P=0.081) were observed in rh-endostatin-treated group. No significant difference was found in TIMP-2 expression between the 2 groups. In combined treatment groups, at the endpoint tumor volumes of concurrent administration group and the endo-first group were remarkably smaller than that in model group (P < 0.001, P=0.003). According to the administration procedure, concurrent administration inhibited tumor growth ber than endo-first treatment did. Both of the combined groups down-regulated the expression of MMP-2 and decreased microvessel density (P < 0.05). Compared with model group, the expression of TIMP-2 was upregulated (P=0.001) as well as EMMPRIN down-regulated (P=0.018) in concurrent administration group. Oppositely, the same results were not observed in the endo-first group. CONCLUSION: The schedule of the concurrent administration group could inhibit the tumor growth better, and it down-regulated MMP-2 expression through TIMP-2 and EMMPRIN, and thus slow down the tumor growth superiorly to another schedule of treatment. 中国肺癌杂志编辑部 2010-06-20 /pmc/articles/PMC6015153/ /pubmed/20681443 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.06.003 Text en 版权所有©《中国肺癌杂志》编辑部2010 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 基础研究
重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织MMP及抗瘤效应观察
title 重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织MMP及抗瘤效应观察
title_full 重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织MMP及抗瘤效应观察
title_fullStr 重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织MMP及抗瘤效应观察
title_full_unstemmed 重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织MMP及抗瘤效应观察
title_short 重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织MMP及抗瘤效应观察
title_sort 重组人血管内皮抑素与多西紫杉醇不同顺序用药调控移植瘤组织mmp及抗瘤效应观察
topic 基础研究
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6015153/
https://www.ncbi.nlm.nih.gov/pubmed/20681443
http://dx.doi.org/10.3779/j.issn.1009-3419.2010.06.003
work_keys_str_mv AT zhòngzǔrénxuèguǎnnèipíyìsùyǔduōxīzǐshānchúnbùtóngshùnxùyòngyàodiàokòngyízhíliúzǔzhīmmpjíkàngliúxiàoyīngguānchá
AT zhòngzǔrénxuèguǎnnèipíyìsùyǔduōxīzǐshānchúnbùtóngshùnxùyòngyàodiàokòngyízhíliúzǔzhīmmpjíkàngliúxiàoyīngguānchá